Over the past two decades, genomics technologies have revolutionized basic research and are also having a significant impact on understanding, predicting and diagnosing disease. Over the same period, the biologics revolution, lead by therapeutic antibodies, has greatly expanded our ability to target proteins that drive cancer and other diseases.
IBBR Seminar Series
Meeting ID: 982 4467 5054
One tap mobile
+13017158592,,98244675054# US (Washington DC)
+13126266799,,98244675054# US (Chicago)
During this presentation I will discuss my laboratory’s collaborative work understanding the structure and function of coronavirus spike proteins, and how we leveraged this information to design novel vaccine antigens that are in four leading COVID-19 vaccines. I will also describe how we were able to rapidly determine the structure of the SARS-CoV-2 spike protein in early 2020 and leverage that information into the design of second-generation spikes that are more stable and express better than our initial antigen. I will also discuss our recent work on spike-directed antibodies.
Brad O'Dell: "cNISTmAb CHO: new living NIST RGTM 10197 and NIST RM 8675"
Lisa Borsuk: "X-STR Marks the Spot"
Meeting number: 120 693 1161
Join by video system
TITLE: Designing ionizable lipids and lipid nanoparticles for mRNA vaccines
Michael D. Buschmann1, Manuel Carrasco1, Suman Alishetty1, Hooda Said1, Lacey Wright1, Mikell Paige2, Pat Gillevet3, Aarthi Narayanan4, Mohamad-Gabriel Alameh5, Ousamah Soliman5, Drew Weissman5, Thomas E. Cleveland IV6, Alexander Grishaev6
1Department of Bioengineering, George Mason University
My laboratory has focused on several areas of human immunology and virology, particularly in studying human immuno-pathology of chronic virus infections. My group was one of the first to use humanized mouse models to study HIV-1 or HBV/HCV infection and pathogenesis. My lab has identified novel virological and immunological mechanisms of HIV-1 and HBV pathogenesis. In recent years, my group has discovered and focused on the Plasmacytoid dendritic cells (pDC)-interferon-macrophage axis in the immuno-pathogenesis and therapy of chronic HIV & HBV infections.
Microorganisms have been used for well over a century to experimentally unlock the mysteries metabolism and to better understand and control processes like fermentation. Much of what we know today about central metabolism was through simple, but ingenious, experimentation on yeast and bacteria. Much more recently, mammalian cells have been developed to treat diseases such as cancer. T-cells modified with chimeric antigen receptors (CAR-T), mesenchymal stem/stromal cells, and induced pluripotent stem cells (iPSC) all have potential for therapeutic applications.